A new study published in the American Journal of Clinical Nutrition demonstrates how DSM Nutritional Products’ weight management ingredient Fabuless®1 exerts its appetite-reducing effects.2 Highlighting differences in digestion between Fabuless and a control fat by an established intestinal sampling technique, the results further substantiate the mechanism behind the reported weight maintenance benefits of Fabuless. With the interest in weight management high on the global agenda, this mechanistic study will strike a chord with scientists and manufacturers keen to deliver effective and sustainable appetite control solutions to the food, beverage and dietary supplements markets.
The controlled, double-blind, cross-over-designed study investigated the mechanism behind the appetite-controlling effect of Fabuless on a group of 16 subjects with healthy weight. Compared to a control milk fat, the fat derived from Fabuless was found to resist absorption, leading to almost double the amount of lipids progressing from the upper gastro-intestinal tract to the sampling site in the small intestine. Interestingly, fatty acid containing crystals were observed in abundance in the Fabuless group. The higher amount of lipids in the middle section of the small intestine and the presence of fatty acid crystals offer coherent evidence for enhanced appetite control through the ileal brake mechanism. In contrast to previous studies in which lipids were infused into the intestine, this unique technique enables the examination of lipids through the natural digestive route.
“We are very pleased with these results as they provide an in depth understanding of the mechanism behind the appetite-reducing effect of Fabuless,” commented Philip Rijken, Head of Nutritional Science Europe and Asia Pacific at DSM Nutritional Products. “The new evidence further validates the enhanced appetite control response to Fabuless by detailing its physiological basis The data add to a previous mechanism of action study3, showing that Fabuless induces a significant delay in food transit time. We expect that these latest insights into the mechanism of action will be received with a lot of interest by the scientific community.”
DSM’s proprietary Fabuless, combines oat and palm oils, both naturally occurring dietary lipids. Fabuless contributes to the body’s appetite regulation. In particular, it enhances the "appetite satisfied" message from the gut system to the brain as part of the body’s normal regulatory mechanism related to energy intake. Fabuless can be consumed on its own or as the key ingredient in a variety of applications including milk, yoghurt, meal replacement drinks and supplement sachets and stick packets.
About DSM Nutritional Products:
DSM Nutritional Products is the world's leading supplier of vitamins, carotenoids and other fine chemicals to the feed, food, pharmaceutical and personal care industries. The business has sales of over $2.5 billion and a long tradition as a pioneer in the discovery of new products, new formulations and attractive applications for all industry segments. More information at http://www.dsmnutritionalproducts.com/ and http://www.qualityforlife.com/
DSM – the Life Sciences and Materials Sciences Company:
Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic prosperity, environmental quality and social equity, which it pursues simultaneously and in parallel. DSM has annual net sales of about $10 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: http://www.dsm.com/
This press release contains forward looking statements. These statements are based on current expectations, estimates and projections of DSM and information currently available to the company. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release.
Forward-looking stats: This press release contains forward looking statements. These statements are based on current expectations, estimates and projections of DSM and information currently available to the company. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release.
1 Fabuless is a registered trademark of Royal DSM N.V.
2 Knutson L., Koenders D.J.P.C., Fridblom H., Viberg A., Sein A., Lennernäs H. (2010). Gastrointestinal metabolism of a vegetable oil emulsion in healthy subjects. American Journal of Clinical Nutrition (June 23, 2010). doi:10.3945/ajcn.2009.28941
3 Haenni A., Sundberg B., Yazdanpandah N., Viberg A., Olsson J. (2009). Effect of fat emulsion (Fabuless) on orocecal transit time in healthy men. Scandinavian Journal of Gastroenterology, Volume 44, Issue 10, pages 1186 - 1190